



**Press Release**  
**Mumbai, 10<sup>th</sup> February 2016**

## **GlaxoSmithKline Pharmaceuticals Limited records 13% Net Sales growth for Q3, FY 2016**

**GlaxoSmithKline Pharmaceuticals Limited** today declared its financial results for the third quarter ended 31<sup>st</sup> December 2015. Net sales at Rs.729 crores recorded a growth of 13% as compared to the same prior year period. Profit Before Tax (PBT) at Rs. 125 crores and Profit After Tax (PAT) at Rs 80 crores grew by 24% and 76% respectively against the same prior year period.

Commenting on the results, **Vaidheesh Annaswamy, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

“Our financial performance for the quarter highlights a return to Net Sales growth. The quarter also includes the vaccine sales arising from the Asset Sales Agreement with Novartis India that concluded at the end of the prior quarter and contributed to 4% of the sales growth.

The cost base in this quarter, as compared to the corresponding prior year quarter, includes an incremental Corporate Social Responsibility cost of 11 Cr as part of our commitment to eliminate Lymphatic Filariasis in India alongside the World Health Organisation (WHO).

Investments at our existing site at Nashik as well as our proposed state of the art manufacturing site at Vemgal, Bangalore, are on track to continue to deliver high quality products to meet the future demands of our India patients.

Our PAT growth of 76% also reflects the reduction in exceptional items as compared to the corresponding prior year quarter.

### **About GlaxoSmithKline Pharmaceuticals Limited**

---

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com)

Media Contacts:  
Ransom D'Souza Head, Corporate Communications  
Email: [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)  
Tel: +91 22 24959203